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ABSTRACT 
Objective: Pharmaceutical salt and cocrystal is a promising alternative method for improving the solubility and dissolution rate of active 
pharmaceutical ingredients. In this work, an attempt was made to improve solubility of ketoconazole (KTZ) using salt formation and 
cocrystallization technique.  
Methods: Salt and cocrystal were prepared using oxalic acid (OXA) and fumaric acid (FUMA) via slurry conversion method. Powder X-Ray 
Diffraction (PXRD), Differential Scanning Calorimetry (DSC) and Scanning Electron Microscope (SEM) techniques were employed to investigate the 
crystallinity, melting point and morphology of salt and cocrystal respectively. KTZ salt and cocrystal were evaluated further for their solubility, 
stability and antifungal activities. 
Results: Synthesis of KTZ OXA salt and KTZ FUMA cocrystal were successfully carried out using slurry conversion method using ethyl acetate 
solvent. The result from PXRD, DSC and SEM analysis confirms the formation of salt and cocrystal of KTZ with OXA and FUMA. Saturation solubility 
studies in water at 25 °C exhibited a remarkable improvement in the drug solubility. KTZ FUMA and KTZ OXA were considered to be stable over the 
period of 1 month confirmed by the stability study. In vitro antifungal activity study revealed that the formation of KTZ OXA and KTZ FUMA did not 
alter the therapeutic activity as an antifungal agent. 
Conclusion: Salt and cocrystal of KTZ (KTZ OXA and KTZ FUMA) exhibit enhanced solubility compare the pure drug. In vitro antifungal study 
revealed that both salt and cocrystal of KTZ retained their antifungal activities. 




(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl] methoxy} phenyl) 
piperazine] (fig. 1 a), is an imidazole derivative with a wide antifungal 
spectrum and possesses some antibacterial activity. It is reported to be 
active in the treatment of systemic blastomycosis, candidiasis, 
coccidioidomycosis, histoplasmosis, paracoccidioidomycosis, and tinea 
of skin and nails [1].  
KTZ commercially available in several dosage forms for oral and 
topical administration. KTZ presents advantage over other imidazole 
derivatives in sustaining adequate blood levels following oral 
administration [2]. KTZ is a weak base and it can be soluble only 
under extremely acidic conditions. It is classified in the 
Biopharmaceutics Classification Scheme (BCS) as a Class II drug, 
since it has a high permeability but low solubility in water (0.087 
mg/l at 25 °C) [3].  
Various methods were used for improving the solubility and dissolution 
rate of KTZ. For example, it had been reported that the solubility and 
dissolution rate of KTZ could be improved by the formation of 
nanoparticle formulation [4], micro emulsion [5], and solid dispersion 
[6]. Crystal engineering is an approach that may improve solubility and 
dissolution rate (bioavailability) of an API. Pharmaceutical co-crystal, 
and salt formation are an example of how crystal engineering concept 
can be utilized to address the poor solubility problem. Salt formation is 
one of the common approaches in modifying the physicochemical 
properties of a drug. However, salt formation is feasible only when the 
API has a suitable ionizable site [7].  
Salt formation of a very weak base API such as KTZ also presents a 
greater risk of disproportionation [8]. Pharmaceutical cocrystal 
provides an alternative way to modify the physicochemical 
properties of APIs, besides salt formation. A cocrystal may be 
defined as a multi component molecular complex in a definite 
stoichiometric ratio of solids that interact through noncovalent 
interactions, predominantly hydrogen bonds [9]. Cocrystallization of 
pharmaceutical compounds may potentially be employed with all 
APIs, including acidic, basic, and nonionizable molecules. A large 
number of pharmaceutically acceptable cocrystal formers exist, 
which potentially increase the scope of cocrystallization over salt 
formation [10].  
Carboxylic acids are known to act as good electron acceptors and 
electron donors and they often participate well in supramolecular 
reactions. Carboxylic acids also come under the category of GRAS 
(Generally Recognised as Safe) as defined by the FDA (the Food and 
Drug Administration) and hence are potential salt and cocrystal 
formers for combination with an API [11].  
A study on KTZ salt and cocrystal formation has been done by Martin et 
al. They prepared KTZ oxalate salt and KTZ fumaric acid cocrystal using 
a solvent mixture of acetone and methanol (1:1) via slow evaporation 
technique [12]. Herein, we reported the preparation of new multi 
component crystals (salt and cocrystal) of KTZ with dicarboxylic acids, 
i.e. oxalic acid (OXA), and fumaric acid (FUMA) (fig. 1 (b) And (c)) via 
slurry conversion method using ethyl acetate as solvent. We employed 
solid-state material characterization techniques such as powder X-ray 
diffraction (PXRD), differential scanning calorimetry (DSC) and scanning 
electron microscope (SEM) to characterize these salts and cocrystal. 




Fig. 1: Molecular structure of KTZ (a), FUMA (b), and OXA (c) 
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MATERIALS AND METHODS 
Materials 
Ketoconazole (KTZ, purity 99.6 %, Piramal Healthcare Limited, 
India.), fumaric acid (FUMA, Sigma–Aldrich Co. LLC), oxalic acid 
(OXA, Sigma–Aldrich Co. LLC), ethyl acetate (ACS grade, JT Baker), 
dimethyl sulphoxide (DMSO; Merck, Germany), and potato Dextrose 
Agar (PDA; Merck, Germany) were used as received. Pathogenic 
fungal including Candida albicans ATCC 10231, Microsporum canis 
ATCC 11621, and Trichophyton rubrum ATCC 28188 were obtained 
from Dipa Puspa Labsains (Indonesia). 
Salt and cocrystal preparation 
Salt and co-crystal of KTZ were prepared by slurry conversion 
method. Equimolar (1:1 mol ratio) quantities of KTZ and 
dicarboxylic acid (OXA and FUMA) were added in 20 ml of ethyl 
acetate and mixed under sonication at 40 °C for 1 h. The resulting 
slurry was filtered through whatman filter paper and the resulting 
solid was dried at 70 °C for 5 h. 
X-Ray powder diffraction (PXRD) 
PXRD patterns were collected by a Rigaku Ultima IV X-ray 
diffractometer (Rigaku Co., Tokyo, Japan) using Cu Kα radiation (λ = 
1.54 Å), a tube voltage of 40 kV, and a tube current of 40 mA. Data 
were collected from 2 to 40 ° at a continuous scan rate of 4 °/min. 
Differential scanning calorimetry (DSC) 
Thermal analysis of the samples was performed on a DSC Q20 
(TA Instruments, DE, USA), calibrated for temperature and cell 
constants using indium. Samples (1-3 mg) crimped in aluminum 
pans were analyzed from 50 to 300 °C with a heating rate of 5 
°C/min. Samples were continuously purged with nitrogen at 50 
ml/min. 
Scanning electron microscopy (SEM) 
The morphology of KTZ, FUMA, OXA, KTZ fumaric acid cocrystal 
(KTZ FUMA), and KTZ oxalate salt (KTZ OXA) were analyzed using a 
JEOL JSM-6510 scanning electron microscopy (SEM, JEOL Ltd., 
Tokyo, Japan). Samples were mounted on a double-faced adhesive 
tape, sputtered with platinum. Scanning electron photographs were 
taken at an accelerating voltage of 5 kV. 
Solubility measurements 
Excess amounts (200 mg) of the samples (KTZ FUMA and KTZ OXA) 
were suspended in 10 ml of water in screw-capped glass vials and 
the slurries were stirred using a magnetic stirrer at room 
temperature (25 °C). After 24 h, the suspensions were filtered 
through a paper filter and solid filtrates were dried and used for 
further PXRD and DSC analysis. The resulting solutions were filtered 
again through a 0.2 μm nylon syringe filter. The filtered aliquots 
were sufficiently diluted the absorbances were measured using a UV 
spectrophotometer (model U-2900, Hitachi, Japan) at a wavelength 
of 270 nm. 
Stability studies 
Accurately weighed samples (approximately 50 mg) placed in 10 ml 
capped (closed condition) and uncapped glass vials (open condition) 
were placed into a stability chamber (Type KBF 720, Binder, 
Germany) at 40 °C/75 % RH for one month, then the samples were 
analyzed by PXRD and DSC. 
In vitro antifungal activity study 
Fungal species used in this study were Candida albicans ATCC 
10231, Microsporum canis ATCC 11621, and Trichophyton rubrum 
ATCC 28188. Antifungal activity was determined by disc diffusion 
assay. All samples (KTZ, KTZ FUMA and KTZ OXA) were dissolved in 
dimethyl sulphoxide at concentration 1 mg/ml and sterilized using 
filtration method with 0.22 μm membrane filters (Iwaki, Japan). The 
medium used were PDA. The 6 mm diameter disc (Whatman, USA) 
was impregnated with 20 μl of the sample and placed on inoculated 
agar (agar with mixture of mycelium and conidia of fungi). DMSO 
was used as negative control.  
The inoculated plates were incubated at 25 °C for 48 h for fungal 
growth. Antifungal activity was evaluated by measuring the 
inhibition zone against those fungal species. All inhibition assays 
and controls were carried out duplicate. SPSS program was used for 
data analysis. 
RESULTS AND DISCUSSION 
XRD analysis 
Powder x-ray diffraction is a fingerprint technique to characterize 
the solid state. Every crystal form of a compound produces its own 
characteristic X-Ray diffraction pattern [13]. If the resulting PXRD of 
the product is different from the starting components (the API and 
salt former/coformer), then it may be inferred that a new solid 
phase has been formed [9]. The PXRD diffractograms of KTZ, FUMA, 
OXA, KTZ FUMA, and KTZ OXA were compared in fig. 2 and 3.  
The PXRD spectrum of KTZ FUMA, and KTZ OXA revealed that a new 
crystalline form distinct from the starting components had been 
generated. The characteristic peaks of KTZ, FUMA, OXA, KTZ FUMA, 
and KTZ OXA at various diffraction angles (2θ) are shown in table 1. 
 
 
Fig. 2: PXRD pattern of KTZ (a), FUMA (b), KTZ FUMA (c) 
 
 
Fig. 3: PXRD pattern of KTZ (a), OXA (b), KTZ OXA (c) 
 
Thermal analysis 
Thermal property of an API may be modified by cocrystal and salt 
formation. DSC has been shown to analyze solid-state interactions 
between drug and salt former or coformer through the appearance, 
shifts or disappearance of endothermal or exothermal effects [14]. 
DSC experiments were carried out to investigate the thermal 
properties of KTZ, FUMA, OXA, KTZ FUMA, and KTZ OXA. The DSC 
thermograms are shown in fig. 4 and 5. Ketoconazole showed a 
single endothermic peak at 149.97 °C. FUMA and OXA exhibited a 
single endothermic peak at 295.84 °C, and 189.98 °C which 
corresponds to the melting point. KTZ FUMA and KTZ OXA exhibited 
sharp melting endotherms at temperatures significantly different 
from those of the drug and the salt former/coformer, suggesting the 
formation of a new crystalline phase. KTZ FUMA exhibited single 
melting point at 169.07 °C between the melting point of KTZ and 
FUMA. KTZ-OXA shows melting point higher than the melting point 
of KTZ and OXA, which is 197.02 °C. Similar melting point value 
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were also found by Martin et al. for KTZ fumaric acid cocrystal and 
KTZ oxalate salt [12]. A single endothermic peak for KTZ FUMA and 
KTZ OXA indicated in a homogeneous solid phase, and also the 
absence of any bound solvent (solvate) or water in lattice crystal [9]. 
There is no correlation between the melting points of the salt 
former/coformer with their respective salt and cocrystal. 
 
Table 1: 2θ position of pure KTZ, salt former/coformer and its salt/cocrystal at various diffraction angles (2θ °) 
2θ position 
KTZ FUMA OXA KTZ FUMA KTZ OXA 
6.460 18.48 14.92 6.660 11.92 
7.180 20.54 18.80 7.880 13.22 
10.48 22.76 22.94 12.06 17.70 
15.92 25.78 24.54 15.16 18.44 
17.34 26.72 27.22 16.82 19.92 
17.40 28.60 29.06 17.12 20.40 
19.20 28.74 31.04 17.24 21.78 
19.62 29.36 33.06 17.70 25.36 
19.88 37.80 37.42 18.16 28.04 
20.20 37.90 38.80 19.12 28.12 
20.24  42.10 20.14 29.82 
20.54   21.42  
21.10   23.70  
21.26   23.80  
23.60   25.58  
27.40     
 
The differences in melting points between KTZ, and its salt or 
cocrystal might be attributable to interaction between API and 
salt/cocrystal forming agent, altered changes in intermolecular 
interactions, and crystal structure [15]. Schultheiss and Newman 
[16] conducted a survey on melting points of 50 reported 
cocrystalline samples, and found that: 51 % had melting points 
between those of the API and coformer; 39 % lower than that of 
either component; 6 % higher than that of either component, and 4 
% had the same melting point as either the API or conformer. 
 
 
Fig. 4: DSC thermograms of KTZ (a), KTZ FUMA (b), FUMA (c) 
 
 
Fig. 5: DSC thermograms of KTZ (a), KTZ OXA (b), OXA (c) 
 
SEM analysis 
SEM analysis (fig. 6) has been performed for the KTZ, FUMA, OXA, 
KTZ FUMA, and KTZ OXA. SEM images of the KTZ indicated 
irregular-shaped particles approximately 5–30 µm in diameter. 
FUMA and OXA exhibited irregular shape with larger in size and 
smooth surface. KTZ FUMA and KTZ OXA also exhibited irregular 
shape similar with those of the pure drug. From the SEM analysis, 
the KTZ FUMA showed reduced in particle size. 
 
Fig. 6: SEM images of KTZ (a), FUMA (b), OXA (c), KTZ FUMA (d), KTZ OXA (e) 
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Solubility 
Solubility is defined as the concentration of the substance in solution 
that is in chemical equilibrium with an excess of the undissolved 
substance [9]. Solubility of KTZ OXA and KTZ FUMA were measured 
in deionized water at 25 °C. The equilibrium solubility values are 
provided in table 2. The reasons for solubility enhancement may be 
described on the basis of the solubility of the salt former/coformer 
in water and as a result of a change in the crystal energy (∆Hsolvation
 
) 
[9, 17]. In the present study, we found an inverse correlation 
between the melting point and solubility. KTZ OXA, which has a 
higher melting point, has a lower solubility than KTZ FUMA, which 
has a lower melting point. Similar results had also been reported by 
other researchers for other API’s [9, 18-19]. The solid residues 
obtained after the solubility studies were then characterized by 
PXRD and DSC. PXRD patterns (fig. 7) and DSC analysis results (table 
3) of KTZ OXA and KTZ FUMA cocrystal were found to be similar to 
their original forms indicating both salt and cocrystal were stable 
after 24 hours of solubility studies in water. 
Table 2: Saturation solubility of pure KTZ, KTZ FUMA and KTZ 
OXA 
Sample Saturation solubility (mg/l) 
KTZ 0.087  
FUMA 6300  
OXA 143 000  
KTZ FUMA 2723.33 
KTZ OXA 1484.33 
 
 
Fig. 7: PXRD pattern of KTZ FUMA before solubility (a), KTZ 
FUMA after solubility (b), KTZ OXA before solubility (c), KTZ 
OXA after solubility (d) 
 
Table 3: Melting point of KTZ FUMA and KTZ OXA before and 
after solubility 
Sample MP (oC) 
KTZ FUMA before solubility 169.07 
KTZ FUMA after solubility 169.27 
KTZ OXA before solubility 197.02 
KTZ OXA after solubility 196.97 
 
Stability 
Physical stability of KTZ FUMA and KTZ OXA was investigated at 40 
°C/75 % RH for one month. Accelerated stability condition, such as 
40 °C/75 % RH, is commonly used for early studies on solid 
materials based on ICH guidelines. The results of PXRD analysis 
demonstrate that the PXRD patterns of KTZ FUMA and KTZ OXA did 
not change (fig. 8). The DSC of these samples did not show any 
additional peaks (table 4). This analysis indicates that KTZ FUMA 
and KTZ OXA were stable under these conditions. The results of 
solubility and stability measurements imply that KTZ FUMA and KTZ 
OXA can be selected for further development. 
 
Fig. 8: PXRD pattern in stability study at 40o
 
C/75% RH of KTZ 
FUMA day 0 (a), KTZ FUMA day 30 in open condition (b), KTZ FUMA 
day 30 in close condition (c), KTZ OXA day 0 (d), KTZ OXA day 30 in 
open condition (e), KTZ OXA day 30 in close condition (f) 
Table 4: Melting point of KTZ FUMA and KTZ OXA before and 
after stability study 
Sample MP (oC) 
KTZ FUMA (day 0) 169.07 
KTZ FUMA (day 30_40 o 169.39 C/75 % RH_open) 
KTZ FUMA (day 30_40 o 168.72 C/75 % RH_close) 
KTZ OXA (day 0) 197.02 
KTZ OXA (day 30_40 o 196.66 C/75 % RH_open) 
KTZ OXA (day 30_40 o 196.55 C/75 % RH_close) 
 
In vitro antifungal activity study 
Fig. 9 shows the comparison of antifungal activities of KTZ compare 
to KTZ FUMA and KTZ OXA. It is shown that all of KTZ samples have 
no significant difference in inhibiting the growth of fungi 
(Microsporum canis, Trichophyton rubrum, and Candida albicans) 
(P>0.05). This study revealed that the formation of KTZ oxalate salt 
(KTZ OXA) and KTZ fumaric acid cocrystal (KTZ FUMA) did not alter 
the therapeutic activity as an antifungal agent. There are three 
general mechanisms of action of the antifungal agents: cell 
membrane disruption, inhibition of cell division, and inhibition of 
cell wall formation. Structure activity studies revealed that the 
imidazole ring can be replaced by a bioisosteric triazole ring without 
affecting the antifungal activity, but achieving higher selectivity of 
the fungal targets [20]. 
 
 




In the present study, FUMA and OXA were successfully used as 
coformer and salt fomer (counter ion) for the improvement of the 
solubility of KTZ via cocrystallization and salt formation process. 
The characteristics of salt and cocrystals inferred from the thermal 
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behavior from DSC analysis and diffraction pattern from PXRD 
analysis confirmed the formation of new solid forms of the KTZ. The 
KTZ salt and cocrystal showed enhanced solubility and were found 
to be stable over the period of one month confirmed by stability 
study. From the in vitro antifungal study, it is shown that KTZ FUMA 
and KTZ OXA retained the therapeutic activity as an antifungal 
agent.  
ABBREVIATION 
API-Active Pharmaceutical Ingredients, BCS-Biopharmaceutics 
Classification Scheme, DSC-Differential Scanning Calorimetry, FDA-
Food and Drug Administration, FUMA-Fumaric acid, GRAS-Generally 
Recognised as Safe, KTZ-Ketoconazole, MP-Melting point, OXA-
Oxalic acid, PXRD-Powder X-ray Diffraction, RH-Relative Humidity, 
SEM-Scanning Electron Microscope 
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